BioSpace News Archive

Visgenx, Inc. announced that the Company will be presenting results from pre-clinical studies of its gene therapy candidate for dry AMD at the American Society of Gene and Cell Therapy 2023 Annual Meeting being held May 16-20 at the Los Angeles Convention Center.

Rockwell Medical, Inc., a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, announced financial and operational results for the three months ended March 31, 2023.

Hummingbird Bioscience announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma.

First Wave BioPharma, Inc. announced that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on Tuesday, June 6 11:45 AM in Room 104A.

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.

Avalo Therapeutics, Inc. announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will attend and present at the ATS 2023 Respiratory Innovation Summit, hosted by the American Thoracic Society, on May 19-20, 2023 in Washington, DC.

Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the first quarter 2023 and provided a business update.

Virios Therapeutics, Inc. announced that it has submitted final toxicology reports as per Food & Drug Administration request as part of their overall review of the Company’s Phase 3 proposal.

Orchard Therapeutics, a global gene therapy leader, announced various business accomplishments along with its financial results for the quarter ended March 31, 2023.

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, reported first quarter financial results for the period ending March 31, 2023.